B Cell News and Research

RSS

First Edition: September 29, 2010

In today's headlines, reports about the continuing politics surrounding the health overhaul, as both parties vie for the loyalty of older voters and First Lady Michelle Obama steps up efforts to promote the new law.

29 Sep 2010

Cancer-causing mutations have minimum effect on tumor growth: Research

Individual cancer causing mutations have a minute effect on tumor growth, increasing the rate of cell division by just 0.4 percent on average, according to new mathematical modeling by scientists at Harvard University, Johns Hopkins University, and other institutions.

29 Sep 2010

Researchers identify gene activator that allows stem cells to transform any type of cell

Emerging Healthcare Solutions, Inc. was energized Monday by news that researchers in North Carolina may have identified the gene activator that allows stem cells to reproduce and become any type of cell in the body.

29 Sep 2010

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Circulating tumor cells may be promising alternative for tumor biopsies

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010

Scientists develop NIA assay to determine drug's differential effects in tumor cells

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.We are making progress toward the goal of understanding how drugs work in different individuals, said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine.

29 Sep 2010

Study finds naturally-derived trehalose inhibits fat cell hypertrophy

Hayashibara Biochemical Laboratories, Inc. based in Okayama City, Okayama Prefecture, Japan, has confirmed that the naturally-derived functional saccharide trehalose has the effect of inhibiting fat cell hypertrophy.

29 Sep 2010

New topical microbicide gel can prevent HIV transmission

Amyloid protein structures are best known for the troubles they pose in the brains of Alzheimer's patients. Now researchers are trying to exploit their presence in a very different place in semen to find a new way to stop HIV.

29 Sep 2010

Sanford-Burnham receives five-year core grant renewal from NCI

The Cancer Center at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has received a five-year core grant renewal from the National Cancer Institute (NCI).

29 Sep 2010

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Roche announced today that it had launched the RTCA Cardio Instrument, the latest member of the xCELLigence product family. The RTCA Cardio Instrument is a medium throughput cell analyzer that utilizes impedance readings to monitor cardiac beating and cellular events in real time.

From Roche Sequencing and Life Science 29 Sep 2010

Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model

GlycoMimetics, Inc., a clinical stage biotechnology company developing a new class of glycobiology based therapies for a broad range of indications, today announced that the journal Blood has published pre-clinical data on the company's lead compound GMI-1070 in a model of sickle cell disease.

29 Sep 2010

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Mayo Clinic, Arizona Cancer Center, and the Translational Genomics Research Institute (TGen).

29 Sep 2010

Scientists discover way of shrinking tumours in cancers

Australian and American scientists have found a way of shrinking tumours in certain cancers - a finding that provides hope for new treatments.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

Covaris enters co-marketing partnership with Illumina for DNA shearing technologies

Covaris Inc. today announced that it has signed a co-marketing agreement with Illumina, Inc. making Covaris DNA shearing technologies the recommended method of shearing with Illumina next-generation sequencing product lines, including HiSeq, HiScanSQ, and Genome Analyzer.

From Illumina, Inc. 29 Sep 2010

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

Saudi FDA approves Apligraf for treatment of diabetic foot ulcers, chronic wounds

Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia. Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the U.S. and around the world.

29 Sep 2010

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.

29 Sep 2010

B Cell News and Research

First Edition: September 29, 2010

Cancer-causing mutations have minimum effect on tumor growth: Research

Researchers identify gene activator that allows stem cells to transform any type of cell

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Circulating tumor cells may be promising alternative for tumor biopsies

CAP cells produce high virus titers upon influenza strain infection

Scientists develop NIA assay to determine drug's differential effects in tumor cells

Study finds naturally-derived trehalose inhibits fat cell hypertrophy

New topical microbicide gel can prevent HIV transmission

Sanford-Burnham receives five-year core grant renewal from NCI

New RTCA Cardio Instrument monitors real-time cardiomyocyte beating and cellular events

Blood journal publishes GMI-1070 pre-clinical data in sickle cell disease model

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Scientists discover way of shrinking tumours in cancers

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Researchers discover new diagnostic test for prostate cancer

Covaris enters co-marketing partnership with Illumina for DNA shearing technologies

New disposable, microfluidic PDMS device for identification of advanced breast cancer

Saudi FDA approves Apligraf for treatment of diabetic foot ulcers, chronic wounds

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

Using single B cell screening to boost antibody discovery eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News